Kiromic Biopharma, Inc.
Kiromic Biopharma, Inc. (KRBP): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.8 months
D/E -1.68 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Kiromic Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$1.8M
Quarterly Burn
$3.6M
Runway
1.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Kiromic Biopharma, Inc.'s pipeline?
Kiromic Biopharma, Inc. (KRBP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kiromic Biopharma, Inc.'s lead drug candidate?
Kiromic Biopharma, Inc.'s most advanced tracked candidate is deltacel (Phase 1) for Non-small cell lung cancer (NSCLC).
What is Kiromic Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kiromic Biopharma, Inc. has approximately 1.8 months of cash runway.
Who is the CEO of Kiromic Biopharma, Inc.?
Brian Hungerford is the chief executive officer of Kiromic Biopharma, Inc. (KRBP).
Get the full picture on Kiromic Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.